Quest's gene test tailors antiplatelet therapy to stent patients
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has provided a saliva-based genetic test to the Scripps Health institute to identify which coronary stent patients will have a poor response to the antiplatelet drug clopidogrel (Plavix).